Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
NCT06347003 · SHASTA-3 Phase 3Completed
- Lead sponsor
- Arrowhead Pharmaceuticals (Industry)
- Enrollment
- 446 (actual)
- Start date
- 22 Jul 2024
- Primary completion
- 12 Jun 2026 (actual)
- Study completion
- 25 Aug 2026
- Last update posted
- 8 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- Plozasiran Injection Drug
- Placebo Drug
Conditions and primary outcome
- Severe Hypertriglyceridemia
Primary outcome
Percent Change in Fasting Serum Triglyceride (TG) Levels from Baseline to Month 12 Compared to Placebo (Baseline, Month 12)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
1 on PubMedPlozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis.
The New England journal of medicine · 2026 Nov 5
PubMed 42981569 (opens in a new tab)DOI 10.1056/NEJMoa2610014 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06347003 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.